Isolation and Pharmacological Investigation of Compounds From Euphorbia matabelensis by Hammadi, Reham et al.
1Department of Pharmacognosy, Interdisciplinary Excellence Centre, 
University of Szeged, Hungary
2School of Biological Sciences, University of Nairobi, Kenya
3Department of Pharmacodynamics and Biopharmacy, University of Szeged, 
Hungary
4Department of Ophthalmology, University of Szeged, Hungary
5Department of Pharmacology and Pharmacotherapy, University of Szeged, 
Hungary
6Interdisciplinary Centre of Natural Products, University of Szeged, Hungary
Corresponding Author: 
Andrea Vasas, Department of Pharmacognosy, Interdisciplinary Excellence 
Centre, University of Szeged, 6720 Szeged, Hungary.




© The Author(s) 2019
Article reuse guidelines:
 sagepub. com/ journals- permissions
DOI: 10.1177/1934578X19863509
 journals. sagepub. com/ home/ npx
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of  the Creative Commons Attribution-NonCommercial 4.0 License 
(http://www. creativecommons. org/ licenses/ by- nc/ 4. 0/) which permits non-commercial use, reproduction and distribution of  the work without further 
permission provided the original work is attributed as specified on the SAGE and Open Access pages (https:// us. sagepub. com/ en- us/ nam/ open- access- at- 
sage).
Isolation and Pharmacological Investigation 
of Compounds From 
Euphorbia matabelensis
Reham Hammadi1, Norbert Kúsz1, Peter W. Mwangi2, Ágnes Kulmány3, István Zupkó3, 
Péter Orvos4,5, László Tálosi1, Judit Hohmann1,6, and Andrea Vasas1
Abstract
This work deals with the isolation and pharmacological investigations of compounds of Euphorbia matabelensis. After multiple sep-
aration process, including thin layer chromatography (TLC), vacuum liquid chromatography, preparative TLC, and high-perfor-
mance liquid chromatography, 1 diterpene (ingenol) and 2 flavonoids (naringenin and eriodictyol) were obtained from the methanol 
extracts prepared from the stems and roots of the plant. The structures of the isolated compounds were determined by nuclear 
magnetic resonance (NMR) and MS measurements and comparison with literature data. All compounds were isolated for the first 
time from the plant. Eriodictyol was detected for the first time from a Euphorbia species. The compounds were tested for their 
antiproliferative (on HeLa, C33a, MCF-7, and MDA-MB-231 cell lines) and GIRK channel blocking activities. None of the com-
pounds proved to be active in these test systems.
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The genus Euphorbia is one of  the six largest genera (Astragalus, 
Bulbophyllum, Psychotria, Euphorbia, Carex, and Begonia) of  flower-
ing plants, with more than 2000 species worldwide, subdivided 
into many subgenera and sections. Members of  this genus are 
characterized by the production of  irritating milky latex.1 For 
centuries, Euphorbia species have been used by various civiliza-
tions as sources of  different medicines, due to their marked 
physiological effects. Diterpene-containing plants of  the genus 
Euphorbia are of  considerable interest as concerns natural 
product drug discovery programs because of  the wide range 
of  potentially valuable biological activities and broad structural 
diversity due to the different polycyclic and macrocyclic skele-
tons and various aliphatic and aromatic ester groups.2 However, 
other compounds, eg, triterpenes, steroids, and flavonoids, also 
occur in these plants and can contribute to their diverse phar-
macological activities.3,4
Species belonging to the family Euphorbiaceae are known 
to contain skin irritant and cocarcinogenic compounds in the 
form of  esters of  the structurally related diterpenes, eg, tigli-
ane, ingenane, and daphanane.5 Many species of  this family are 
used in folk medicine as drugs or as raw materials for medicinal 
preparations, eg, in traditional Chinese medicine they are rec-
ommended for the treatment of  edema, gonorrhea, migraine, 
and warts.2,6
Euphorbia matabelensis Pax (Euphorbiaceae) is a slightly succu-
lent, deciduous shrub or tree, usually growing up to 3-8 m. The 
plant is harvested from the wild for local medicinal use and some-
times to make a gum.7 In Malawi, a root decoction, combined 
with the leaves of  Dichrostachys cinerea, is drunk to treat depression, 
high blood pressure, and swollen lymph glands.7 In Zimbabwe, 
the powdered root is rubbed into scarifications on the breasts as 
a galactagogue for foster mothers. Moreover, the decoction of  
the chopped roots or latices is taken as a purgative in case of  
poisoning and to induce abortion, in which case a few drops are 
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infused in a glass of  milk and the infusion taken by orally.7 The 
latex is taken into drinking water of  chickens to treat diarrhea and 
Newcastle disease.7
Until now, there is only one previous investigation of  E. mata-
belensis, which was carried out by analyzing the latex of  the plant. 
A diterpene of  the ingenane-type parent alcohol with tetradeca-
noic acid ester as the acyl substituent was isolated by chromato-
graphic methods from the latex of  the plant. The ingenol ester 
exhibited irritant activity in mouse ear test.8
As a part of  our research program to discover new bioactive 
compounds from Euphorbia species, the chloroform-soluble 
fraction of  a methanol extract of  E. matabelensis Pax 
(Euphorbiaceae) was investigated. This study resulted in the 
isolation and structure determination of  1 diterpene (ingenol) 
and 2 flavonoids (naringenin and eriodictyol) from this plant. 
All compounds were studied for their antiproliferative activity 
against human tumor cell lines of  gynecological origin, and 
GIRK channel-inhibitory activity using automated patch-
clamp method, as previously several diterpene esters, isolated 
by our group, possessed such pharmacological activities.9,10
The fresh plant material (root [R] and stem [S]) of  E. matabel-
ensis (1.6 kg [R] and 0.9 kg [S]) was chopped and extracted with 
methanol at room temperature. After concentration, the extracts 
were dissolved in 50% aqueous methanol, and solvent-solvent 
partitions were performed with CHCl3 and EtOAc. The CHCl3 
phases were separated and fractionated with the combination of  
different chromatographic methods (column chromatography 
[CC], vacuum liquid chromatography [VLC], preparative thin 
layer chromatography [TLC], and high-performance liquid chro-
matography [HPLC]) to afford 3 compounds (Figure 1).
The structure determination was carried out by spectro-
scopic analysis, using 1- and 2-dimensional nuclear magnetic 
resonance (NMR) (correlated spectroscopy [1H-1H COSY], 
heteronuclear single-quantum correlation spectroscopy 
[HSQC], heteronuclear multiple-bond correlation spectros-
copy [HMBC], and nuclear Overhauser enhancement spectros-
copy) spectroscopy, high-resolution mass spectrometry, and 
comparison of  the spectral data with literature data. Based on 
the NMR and MS investigations, compound 1 was identified as 
ingenol,11 compound 2 as naringenin (4′,5,7-trihydroxyflava-
none),12,13 and compound 3 as eriodictyol (3′,4′,5,7-tetrahy-
droxyflavanone).12,13 All compounds were isolated for the first 
time from E. matabelensis.
Ingenol has been detected previously in several Euphorbia spe-
cies (eg, E. candelabrum, E. coralloides, E. deightonii, E. desmondii, E. 
drupifera, E. erythreaea, E. grandiflora, E. kamerunica, E. kotschyana, E. 
lactea, E. lathyris, E. memoralis, E. millii, E. nerifolia, E. nivulia, E. 
pentagona, E. pseudograntii, E. robbiae, E. royleana, and E. 
sikkimensis).5
Ingenol 3-angelate, the best-known ingenol derivative, is used 
in human therapy (Picato) for the treatment of  actinic keratosis, a 
precancerous skin disease. Moreover, it was reported that treat-
ment of  ingenol derivatives such as ingenol triacetate in HIV-
infected T cells inhibited HIV replication through downregulation 
of  CD4 receptors14,15 and CXCR4 receptors.16
Naringenin was isolated previously from different Euphorbia 
species, eg, E. sikkimensis, E. cuneata, and E. tuckeyana.17-19 The 
antioxidant potential of  naringenin was confirmed in several in 
vitro studies and animal models.20 Furthermore, the compound 
was found to be effective against the atypical multidrug resistant 
subline of  gastric carcinoma and exhibited suppressive effect on 
transforming growth factor-β (TGF-β) signaling pathway, TGF-β 
ligand-receptor interaction; therefore, it could be of  importance 
in several types of  cancer wherein TGF-β plays an important 
role. Naringenin exerted cytotoxic activity against several tumor 
(eg, colon, pancreas, leukemia, stomach, cervix, liver, and breast) 
cell lines.21
Eriodictyol was isolated for the first time from yerba santa 
(Eriodictyon californicum), a plant native to North America.22 
Eriodictyol and its glucoside possessed anti-inflammatory, anti-al-
lergenic, antimicrobial, anticancer, and antioxidant properties.23,24 
Another study has confirmed that a dimer of  naringenin and eri-
odictyol reduced brain damage and neurological deficits.25 
Moreover, eriodictyol enhanced insulin secretion dose-de-
pendently only at high glucose concentration both in mice islets 
and MIN6 cells, improved glucose tolerance, and enhanced 
plasma insulin in nondiabetic and diabetic rats.26
In our study, all compounds (1-3) were tested for their 
antiproliferative and GIRK channel inhibitory activities. The 
antiproliferative effects were tested against 4 human tumor 
cell lines (HeLa and C33a [cervix adenocarcinomas], MCF-7 
and MDA-MB-231 [breast carcinomas]) using the MTT test 
with cisplatin as positive control (IC50 values 12.43 µM 
[HeLa], 3.69 µM [C33a], 5.78 µM [MCF-7], and 19.13 µM 
[MDA-MB-231]). Compounds 1 to 3 exhibited only less than 
20% growth inhibition on the utilized cell lines at 30 µM. To 
Figure 1. Structures of the isolated compounds 1 to 3.
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study the possible potassium channel-blocking capability of  
the investigated compounds, screening of  the isolated com-
ponents was performed on a GIRK channel expressing cell 
line. Compounds were screened at 2 concentrations (1 and 
10 µM) on 2 cells. Propafenone was used as positive control 
(48.73% ± 2.33% inhibition at 1 µM). All compounds pos-
sessed weak blocking activity on GIRK channels (inhibition 
% 8.29 ± 1.04 for 1, 12.18 ± 1.39 for 2, and 13.50 ± 2.69 for 
3, at 10 µM).
In conclusion, 3 compounds among them 1 diterpene (inge-
nol [1]) and 2 flavanones (naringenin [2] and eriodictyol [3]) 
were isolated from the roots and stems of  E. matabelensis. All 
components were detected for the first time in the plant. 
Moreover, eriodictyol was detected for the first time in genus 
Euphorbia. It can be stated that E. matabelensis belongs to that 




CC was performed on polyamide (MP Biomedicals Germany 
GmbH, Germany). Normal phase VLC was carried out on 
silica gel (Kieselgel 60 GF254, 15 µm, Merck, United States). 
TLC was carried out on Kieselgel 60 RP-18 F254 and Kieselgel 
60 F254 (Merck). Spots on UV active silica gel were detected 
under UV light (245 and 336 nm) and made visible with vanil-
lin sulfuric acid and heating at 105°C for 2 minutes. The 
HPLC system was comprised of  a Waters 600 controller, 
Waters 600 pump, and Waters 2998 photodiode array detector 
on an NP column (LiChroCART, 250-4, 5 µm). In case of  the 
gradient elution, the mobile phase consisted of  solvent A 
(cyclohexane) and solvent B (EtOAc) with a flow rate of  1.5 
mL/min. The initial mobile phase composition was main-
tained at 80% solvent A for 1 minute, changed linearly to 20% 
(1-10 minutes) and held 2 minutes (10-11 minutes), then fol-
lowed by a return to the initial conditions within 1 minute 
(11-12 minutes) and kept 2 minutes (12-14 minutes) for the 
chromatograph column equilibrium. The injection volume 
was of  25 µL. The data were acquired and processed with the 
Empower software.
NMR spectra were recorded in CD3OD on a Bruker Avance 
DRX 500 NMR spectrometer at 500 MHz (1H) and 125 MHz 
(13C). The signals of  the deuterated solvents were taken as a 
reference. Two-dimensional experiments were performed with 
standard JEOL or standard Bruker software. In the COSY, 
HSQC, and HMBC experiments, gradient-enhanced versions 
were applied. The MS characterization was performed using an 
API2000 triple quadrupole mass spectrometer. The used ion 
source was turbo ESI source.
All solvents used for CC were of  at least analytical grade 
(VWR Ltd., Szeged, Hungary). Ultrapure water was 
prepared with a Milli-Q water purification system (Millipore, 
France).
Plant Material
The stem and root (2.5 kg, fresh weight) of  E. matabelensis Pax 
were collected in Kenya (Matuu subcounty, Machakos county S 
01°04.579′ E 037°35.065′), Africa, in June 2016, and identified 
by Patrick Chalo Mutiso taxonomist. A voucher specimen (No. 
UON 2016/501) has been deposited at the Herbarium of  the 
School of  Biological Sciences, University of  Nairobi, Kenya.
Extraction and Isolation
The fresh stems (S) and roots (R) of  E. matabelensis (1.6 kg [S] 
and 0.9 kg [R]) were chopped and separately percolated with 
methanol (35 L) at room temperature. The crude methanol 
extracts were concentrated under reduced pressure (51 g [S] 
and 28 g [R]), and after solvent-solvent partition with CHCl3 
and EtOAc, the CHCl3 phases were separated by polyamide 
column chromatography with MeOH-H2O gradient system 
(2:3, 3:2, 4:1, and 1:0) as eluent, to get four-four fractions (S-1-
S-4 and R-1–R-4) from stems and roots. The fractions were 
monitored by TLC with the use of  CHCl3-MeOH 95:5 as a 
mobile phase. After UV detection, the plate was sprayed with 
concentrated sulfuric acid and heated at 105°C for 2 minutes. 
Based on the TLC determination, it could be observed that 
fractions of  stems and roots were differed from each other; 
therefore, their further purification was performed separately.
Fraction R1 (1.2 g) was separated by VLC on silica gel with 
a gradient system of  CHCl3-MeOH (98:2, 95:5, 9:1, 8:2, 7:3, 
and 1:1; 100 mL of  each). Fraction R1/4 (47 mg) was purified 
by preparative TLC on reversed-phase silica gel with MeOH-
H2O 4:1 to yield compound 1 (16.7 mg).
Fraction S2 (1.59 g) was separated by VLC on silica gel with 
a gradient system of  cyclohexane-EtOAc-EtOH (9:1:0, 8:2:0, 
7:3:0, 6:4:0, 60:30:3, 60:30:5, 6:3:1, and 1:1:1; 25 mL of  each). 
Fraction S2/5 (11.6 mg) was subjected to NP-HPLC purifica-
tion with gradient system of  cyclohexane-EtOAc (flow rate 1.5 
mL/min) to yield compound 2 (tR = 6.3 minutes, 0.8 mg). 
From S2/6 compound 3 (tR = 7.5 minutes, 1.4 mg) was isolated 
by NP-HPLC using the same eluent system and parameters as 
that of  compound 2.
Antiproliferative Assay
The antiproliferative properties of  the isolated compounds 
were determined on a panel of  human malignant cell lines iso-
lated from cervical (HeLa and C33a) and breast carcinomas 
(MCF-7 and MDA-MB-231) purchased from European 
Collection of  Cell Cultures (ECCAC, Salisbury, United 
Kingdom) exception for C33a cells which were from LGC 
Standards GmbH (Wesel, Germany). Cells were cultivated in 
minimal essential medium supplemented with 10% fetal bovine 
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serum, 1% nonessential amino acids, and an antibiotic-antimy-
cotic mixture. All media and supplements were obtained from 
Lonza Group Ltd. (Basel, Switzerland). Near-confluent cancer 
cells were seeded onto a 96-well microplate (5000 cells/well) 
and, after an overnight standing medium containing the tested 
compounds at 10 and 30 µM, was added. After incubation for 
72 hours under cell culture conditions, the living cells were 
assayed by the addition of  20 µL of  5 mg/mL 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solu-
tion. MTT was converted by intact mitochondrial enzymes and 
precipitated as purple crystals during a 4-hour contact period. 
The medium was next removed and formazan was dissolved in 
100 µL of  dimethyl sulfoxide (DMSO) during a 60-minute 
period of  shaking at 37°C. Finally, the reduced MTT was 
assayed at 545 nm using a microplate reader.27 All in vitro 
experiments were carried out on 2 microplates with 5 parallel 
wells. Stock solutions of  the tested compounds (10 mM) were 
prepared in DMSO. The highest DMSO content of  the 
medium (0.3%) did not have any substantial effect on the cell 
proliferation. Cisplatin (Ebewe Pharma GmbH, Unterach, 
Austria) was used as a reference agent.
GIRK Channel Inhibitory Assay
GIRK ion current was measured using planar patch-clamp 
technology in the whole-cell configuration with a 4 channel 
medium throughput fully automated patch-clamp system 
(Patchliner, Nanion Technologies GmbH, Munich, Germany).28 
The pipetting protocols were controlled by PatchControlHT 
1.09.30 software (Nanion Technologies GmbH., Munich, 
Germany). Data acquisition and online analysis were per-
formed with an EPC-10 Quadro patch-clamp amplifier 
(HEKA Elektronik Dr. Schulze GmbH, Lambrecht/Pfalz, 
Germany) using PatchMaster 2.65 software (HEKA Elektronik 
Dr Schulze GmbH, Lambrecht/Pfalz, Germany). Currents 
were low-pass filtered at 2.9 kHz using the internal Bessel filter 
of  the amplifier and digitized at 10 kHz.
Experiments were carried out on HEK-293 (human embry-
onic kidney) cells stably expressing the GIRK1/4 (Kir3.1/3.4) 
K+ channels.10 Cell line originated from UCL Business Plc. 
(London, Great Britain). Cells were maintained in Dulbecco's 
modified Eagle's medium (Thermo Fisher Scientific Inc., 
Waltham, United States) medium supplemented with 10% fetal 
bovine serum (PAN-Biotech GmbH, Aidenbach, Germany) 
and 182 µg/mL zeocin (Thermo Fisher Scientific Inc., 
Waltham, United States).
Automated patch-clamp experiments were carried out at 
room temperature with a suspension of  stable transfected cell 
line. Suspension of  cells for measurements was derived from 
running cell culture. Cells were maintained in incubator at 
37°C, in 5% CO2. Before experiments, cells were washed twice 
with phosphate buffered saline (Thermo Fisher Scientific Inc., 
Waltham, United States) and then detached with trypsin-eth-
ylenediaminetetraacetic acid (PAN-Biotech GmbH, Aidenbach, 
Germany) for 1 to 3 minutes. Trypsin was blocked with 
serum-containing media. The cell suspension was next centri-
fuged (2 minutes, 100 g), resuspended in serum-free media at a 
final density of  1 × 106-5 × 106 cells/mL, and kept in the cell 
hotel of  the Patchliner. Cells were recovered after 15-30 min-
utes and remained suitable for automated patch-clamp record-
ings for up to 4 hours.
Stock of  extra- and intracellular solutions were made for 
automated patch-clamp recordings. Chemicals were purchased 
from Sigma-Aldrich Corporation (St Louis, United States). All 
solutions were sterile filtered. Aliquots were stored at –20°C 
and warmed up to room temperature before use.
For each compounds isolated from E. matabelensis, a stock 
solution of  test compound (10 mM) was prepared in each case. 
The solubilizing agent was DMSO (Sigma-Aldrich 
Corporation). Aliquots were stored at –20°C. Before experi-
ments, stock solutions were further diluted with high K+ exter-
nal solution to give appropriate concentrations for the 
measurements. The final DMSO concentrations in the tested 
samples were 0.1% or less.
At the beginning of  the recordings, the normal external 
solution (4 mM K+) was replaced to high K+ external solution 
(25 mM K+) in order to increase the current amplitude. After 
2-3 minutes of  control period, the test compounds were added 
to the cells in increasing concentrations (1 and 10 µM), each for 
approximately 3 minutes. Propafenone (1 µM, Sigma-Aldrich 
Corporation) was used as a reference compound. Finally, 
potassium-free external solution was applied to completely 
cease inward potassium currents. The data were corrected with 
the current values measured in the potassium free external 
solution, which served as the baseline.
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2. 255-261.
Hammadi et al. 5
 2. Vasas A, Hohmann J. Euphorbia diterpenes: isolation, struc-
ture, biological activity, and synthesis (2008-2012). Chem Rev. 
2014;114(17):8579-8612.
 3. Shi Q-W, Su X-H, Kiyota H. Chemical and pharmacolog-
ical research of  the plants in genus Euphorbia. Chem Rev. 
2008;108(10):4295-4327.
 4. Noori M, Chehreghani A, Kaveh M. Flavonoids of  17 species 
of  Euphorbia (Euphorbiaceae) in Iran. Toxicol Environ Chem. 
2009;91(4):631-641.
 5. Evans FJ, Taylor SE. Pro-inflammatory, tumour-promoting and 
antitumour diterpenes of  the plant families Euphorbiaceae and 
Thymeleaceae. In: Herz W, Grisebach H, Kirby GW, eds. Pro-
gress in the Chemistry of  Organic Natural Products. Wien, New York: 
Springer; 1983:Vol. 44. 1-99.
 6. Liang Q-L, Dai C-C, Jiang J-H, Tang Y-P, Duan J-A. A new 
cytotoxic casbane diterpene from Euphorbia pekinensis. Fitoterapia. 
2009;80(8):514-516.
 7. Schmelzer GH, Gurib-Fakim A. Plant Resources of  Tropical Africa 
11(1), Medicinal plants1. PROTA Foundation/ Backhuys pub-
lisher/CTA: Wageningen, The Netherlands; 2008:276.
 8. Gundidza M, Sorg B, Hecker E. A skin irritant principle from 
Euphorbia matabelensis Pax. J Ethnopharmacol. 1993;39(3):209-212.
 9. Vasas A, Rédei D, Csupor D, Molnár J, Hohmann J. Diterpe-
nes from European Euphorbia species serving as a new proto-
type for natural product-based drug discovery. Eur J Org Chem. 
2012;2012(27):5115-5130.
 10. Vasas A, Forgo P, Orvos P, et al. Myrsinane, premyrsinane, and 
cyclomyrsinane diterpenes from Euphorbia falcata as potassium 
ion channel inhibitors with selective G protein-activated inwardly 
rectifying ion channel (GIRK) blocking effects. J Nat Prod. 
2016;79(8):1990-2004.
 11. Appendino G, Tron GC, Cravotto G, Palmisano G, Jakupovic J. 
An expeditious procedure for the isolation of  ingenol from the 
seeds of  euphorbia lathyris. J Nat Prod. 1999;62(1):76-79.
 12. da Silva LAL, Faqueti LG, Reginatto FH, dos Santos ADC, Bari-
son A, Biavatti MW. Phytochemical analysis of  Vernonanthura 
tweedieana and a validated UPLC-PDA method for the quantifica-
tion of  eriodictyol. Rev Bras Farmacogn. 2015;25(4):375-381.
 13. Markham KR, Geiger H. 1H nuclear magnetic resonance spec-
troscopy of  flavonoids and their glycosides in hexadeuterodi-
methylsulfoxide. In: Harborne JB, ed. The Flavonoids. Advances in 
Research Since 1986. London: Chapman & Hall; 1994:441-497.
 14. Hasler CM, Acs G, Blumberg PM. Specific binding to protein 
kinase C by ingenol and its induction of  biological responses. 
Cancer Res. 1992;52(1):202-208.
 15. Chowdhury IH, Koyanagi Y, Kobayashi S, et  al. The phorbol 
ester TPA strongly inhibits HIV-1-induced syncytia formation 
but enhances virus production: possible involvement of  protein 
kinase C pathway. Virology. 1990;176(1):126-132.
 16. Kedei N, Lundberg DJ, Toth A, Welburn P, Garfield SH, Blum-
berg PM. Characterization of  the interaction of  ingenol 3-ange-
late with protein kinase C. Cancer Res. 2004;64(9):3243-3255.
 17. Yang D-S, Wei J-G, Yang Y-P, Yang Y-H, Li X-L. Chemical con-
stituents of  Euphorbia sikkimensis. Zhongguo Zhong Yao Za Zhi. 
2013;38(23):4094-4098.
 18. Awaad AS, Al-Jaber NA, Moses JE, El-Meligy RM, Zain ME. 
Antiulcerogenic activities of  the extracts and isolated flavonoids 
of  Euphorbia cuneata Vahl. Phytother Res. 2013;27(1):126-130.
 19. Wesolowska O, Wisniewski J, Duarte N, Ferreira M-JU, Michalak 
K. Inhibition of  MRP1 transport activity by phenolic and terp-
enic compounds isolated from Euphorbia species. Anticancer Res. 
2007;27(6B):4127-4133.
 20. Joshi R, Kulkarni YA, Wairkar S. Pharmacokinetic, pharmacody-
namic and formulations aspects of  naringenin: an update. Life Sci. 
2018;215:43-56.
 21. Duarte N, Lage H, Abrantes M, Ferreira M-JU. Phenolic com-
pounds as selective antineoplasic agents against multidrug-resist-
ant human cancer cells. Planta Med. 2010;76(10):975-980.
 22. Geissman TA. The isolation of  eriodictyol and homoe-
riodictyol. An improved procedure. J Am Chem Soc. 
1940;62(11):3258-3259.
 23. Lee JK. Anti-inflammatory effects of  eriodictyol in lipopolysac-
charide-stimulated raw 264.7 murine macrophages. Arch Pharm 
Res. 2011;34(4):671-679.
 24. Hu Q, Zhang DD, Wang L, Lou H, Ren D. Eriodictyol-7-O-glu-
coside, a novel Nrf2 activator, confers protection against cispla-
tin-induced toxicity. Food Chem Toxicol. 2012;50(6):1927-1932.
 25. Campos PM, Prudente AS, Horinouchi CD, et  al. Inhibitory 
effect of  GB-2a (I3-naringenin-II8-eriodictyol) on melanogene-
sis. J Ethnopharmacol. 2015;174:224-229.
 26. Hameed A, Hafizur RM, Hussain N, et al. Eriodictyol stimulates 
insulin secretion through cAMP/PKA signaling pathway in mice 
islets. Eur J Pharmacol. 2018;820:245-255.
 27. Mosmann T. Rapid colorimetric assay for cellular growth and sur-
vival: application to proliferation and cytotoxicity assays. J Immu-
nol Methods. 1983;65(1-2):55-63.
 28. Nanion Technologies - Products - Patchliner. [Online]. https://
www. nanion. de/ en/ products/ patchliner. html Accessed Decem-
ber 19, 2018.
